Approval · Notice of Compliance 36949 · 2026
IMFINZI: Notice of Compliance 36949
Issued February 20, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36949
- Date
- February 20, 2026
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication: Resectable Non-Small Cell Lung Cancer: IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable Stage II, IIIA, or IIIB (T3-4 N2) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMFINZI | Not yet assigned | — |
Medicinal ingredients
- DURVALUMAB 50 MG per ML